Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study

Introduction Hyperkalemia, one of the most important electrolyte abnormalities of chronic kidney disease (CKD), often limits the use of renin–angiotensin–aldosterone system inhibitors and can increase in the postprandial period. In this study we report a real-world experience with the new non-adsorb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of nephrology 2024-05, Vol.37 (4), p.1077-1084
Hauptverfasser: Riccio, Eleonora, D’Ercole, Anna, Sannino, Anna, Hamzeh, Sarah, De Marco, Oriana, Capuano, Ivana, Buonanno, Pasquale, Rizzo, Manuela, Pisani, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Hyperkalemia, one of the most important electrolyte abnormalities of chronic kidney disease (CKD), often limits the use of renin–angiotensin–aldosterone system inhibitors and can increase in the postprandial period. In this study we report a real-world experience with the new non-adsorbed potassium binder patiromer in stage 3b-4 CKD patients. Moreover, we performed a cross-sectional analysis to evaluate, for the first time, the efficacy of patiromer in the control of postprandial potassium concentrations. Methods We retrospectively collected data of 40 patients at the time of patiromer initiation (T0), and after 2 (T2), 6 (T6) and 12 (T12) months of treatment. For cross sectional analysis, a blood sample was collected 2 h after the main meal for the evaluation of postprandial potassium concentrations. Results Eighty-two point five percent of patients (33/40) reached normal potassium concentrations at T2. Serum potassium significantly decreased at T2 compared to T0 (5.13 ± 0.48 vs 5.77 ± 0.41 mmol/L, respectively; p  
ISSN:1724-6059
1724-6059
DOI:10.1007/s40620-024-01897-9